CC-401 hydrochloride

• CAT Number: I001691
• CAS Number: 1438391-30-0
• Molecular Formula: C22H25ClN6O
• Molecular Weight: 424.93
• Purity: ≥95%
• Synonyms: 3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole hydrochloride
• Target: JNK
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IUPAC Name: 3-[3-(2-piperidin-1-ylethoxy)phenyl]-5-(1H-1,2,4-triazol-5-yl)-1H-indazole;hydrochloride
• InChI: InChI=1S/C22H24N6O.ClH/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21;/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27);1H
• InChIKey: OIBVXKYKWOUGAO-UHFFFAOYSA-N
• SMILES: C1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5.Cl

CC-401 hydrochloride (Cat No.:I001691) is a second-generation ATP-competitive inhibitor of c-Jun N terminal kinase (JNK). JNK is a protein kinase involved in various cellular processes, including cell proliferation, apoptosis, and inflammation. By inhibiting JNK, CC-401 hydrochloride has the potential to disrupt aberrant JNK signaling in cancer cells, leading to antineoplastic effects. Preclinical studies have demonstrated its ability to inhibit tumor growth and promote apoptosis in cancer models. CC-401 hydrochloride is being explored as a therapeutic agent for the treatment of various malignancies and may hold promise as a targeted therapy option in oncology.

Reference

[1]. Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK, Brenner DA.JNK mediates hepatic ischemia reperfusion injury.J Hepatol. 2005 Jun;42(6):850-9. Epub 2005 Apr 7.
[2]. Flanc RS, et al. A pathogenic role for JNK signaling in experimental anti-GBM glomerulonephritis. Kidney Int. 2007 Sep;72(6):698-708.
[3]. Kanellis J, et al. JNK signalling in human and experimental renal ischaemia/reperfusion injury. Nephrol Dial Transplant. 2010 Sep;25(9):2898-908.